Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT/3BNC117联合疗法在降低HIV-1病毒载量方面的有效性
CTR20211141Phase 2Terminated
- Sponsor
- Frontier Biotechnologies Inc.
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of albuvirtide + 3BNC117 in human immunodeficiency virus infection (HIV), sponsored by Frontier Biotechnologies Inc.. Started Jun 2021; status: terminated.
02
Drugs
albuvirtide + 3BNC117
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on CTR20211141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211141.